Histological response, pattern of tumor destruction and clinical outcome after neoadjuvant chemotherapy including bevacizumab or cetuximab in patients undergoing liver resection for colorectal liver metastases

European Journal of Surgical Oncology

Volumn 41, Issue 7, 2015, Pages 868-874

  Stremitzer, S ^a   Stift, J ^a   Singh, J ^a   Starlinger, P ^a   Gruenberger, B ^b   Tamandl, D ^a   Gruenberger, T ^c  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b St John of God Hospital   (Austria)

^c KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

Author keywords

Bevacizumab; Cetuximab; Colorectal liver metastases; Histological response; Pattern of tumor destruction; Survival

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLUOROPYRIMIDINE; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; FLUOROURACIL; KRAS PROTEIN, HUMAN; MONOCLONAL ANTIBODY; ONCOPROTEIN; PLATINUM COMPLEX; RAS PROTEIN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURGERY; CANCER SURVIVAL; CLINICAL EVALUATION; COLORECTAL LIVER METASTASIS; FEMALE; FIBROSIS; FOLLOW UP; HISTOLOGY; HUMAN; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR CELL DESTRUCTION; TUMOR FIBROSIS; TUMOR NECROSIS; ADJUVANT CHEMOTHERAPY; ANALOGS AND DERIVATIVES; CANCER STAGING; CLINICAL TRIAL; COLORECTAL TUMOR; COMPUTER ASSISTED TOMOGRAPHY; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; DRUG EFFECTS; GENETICS; KAPLAN MEIER METHOD; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS; MIDDLE AGED; NECROSIS; PATHOLOGY; PROCEDURES; PROPORTIONAL HAZARDS MODEL; RADIOGRAPHY; SECONDARY; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HEPATECTOMY; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NECROSIS; NEOADJUVANT THERAPY; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84930755337     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2015.03.223     Document Type: Article

References (24)

1. H. Hurwitz, L. Fehrenbacher, W. Novotny, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335 2342
2. E. Van Cutsem, C.H. Kohne, E. Hitre, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer N Engl J Med 360 2009 1408 1417
3. L.B. Saltz, S. Clarke, E. Diaz-Rubio, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study J Clin Oncol: official journal of the American Society of Clinical Oncology 26 2008 2013 2019
4. V. Heinemann, L.F. von Weikersthal, T. Decker, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial Lancet Oncol 15 2014 1065 1075
5. A. Venook, D. Niedzwiecki, H.J. Lenz, et al. CALGB/SWOG 80405: phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC) J Clin Oncol: official journal of the American Society of Clinical Oncology 32 5s 2014 (suppl; abstr LBA3)
6. S. Kopetz, G.J. Chang, M.J. Overman, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy J Clin Oncol: official journal of the American Society of Clinical Oncology 27 2009 3677 3683
7. B. Nordlinger, H. Sorbye, B. Glimelius, et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial Lancet Oncol 14 2013 1208 1215
8. B. Gruenberger, D. Tamandl, J. Schueller, et al. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer J Clin Oncol: official journal of the American Society of Clinical Oncology 26 2008 1830 1835
9. J. Primrose, S. Falk, M. Finch-Jones, et al. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the new EPOC randomised controlled trial Lancet Oncol 15 2014 601 611
10. L. Rubbia-Brandt, E. Giostra, C. Brezault, et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery Ann Oncol: official journal of the European Society for Medical Oncology/ESMO 18 2007 299 304
11. D.G. Blazer 3rd, Y. Kishi, D.M. Maru, et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases J Clin Oncol: official journal of the American Society of Clinical Oncology 26 2008 5344 5351
12. T. Gruenberger, D. Arnold, and L. Rubbia-Brandt Pathologic response to bevacizumab-containing chemotherapy in patients with colorectal liver metastases and its correlation with survival Surg Oncol 21 2012 309 315
13. M. Klinger, D. Tamandl, S. Eipeldauer, et al. Bevacizumab improves pathological response of colorectal cancer liver metastases treated with XELOX/FOLFOX Ann Surg Oncol 17 2010 2059 2065
14. F. Loupakis, M. Schirripa, C. Caparello, et al. Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab Br J Cancer 108 2013 2549 2556
15. E.A. Eisenhauer, P. Therasse, J. Bogaerts, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J cancer 45 2009 228 247
16. D. Dindo, N. Demartines, and P.A. Clavien Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey Ann Surg 240 2004 205 213
17. Y. Fong, J. Fortner, R.L. Sun, M.F. Brennan, and L.H. Blumgart Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases Ann Surg 230 1999 309 318 discussion 18-21
18. D. Ribero, H. Wang, M. Donadon, et al. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases Cancer 110 2007 2761 2767
19. D.A. Wicherts, R.J. de Haas, M. Sebagh, et al. Impact of bevacizumab on functional recovery and histology of the liver after resection of colorectal metastases Br J Surg 98 2011 399 407
20. G.A. Poultsides, F. Bao, E.L. Servais, et al. Pathologic response to preoperative chemotherapy in colorectal liver metastases: fibrosis, not necrosis, predicts outcome Ann Surg Oncol 19 2012 2797 2804
21. S. Pernot, M. Terme, T. Voron, et al. Colorectal cancer and immunity: what we know and perspectives World J Gastroenterol: WJG 20 2014 3738 3750
22. J. Shindoh, E.M. Loyer, S. Kopetz, et al. Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases J Clin Oncol: official journal of the American Society of Clinical Oncology 30 2012 4566 4572
23. G. Folprecht, T. Gruenberger, W.O. Bechstein, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial Lancet Oncol 11 2010 38 47
24. T. Gruenberger, J. Bridgewater, I. Chau, et al. Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial Ann Oncol: official journal of the European Society for Medical Oncology/ESMO 26 2015 702 708